Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema

This article was originally published here

The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the

The post Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply